- Home
- FLNC vs EVO Comparison
FLNC vs EVO Comparison
Compare FLNC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- EVO
- Stock Information
- Founded
- FLNC 2018
- EVO 1993
- Country
- FLNC United States
- EVO Germany
- Employees
- FLNC N/A
- EVO N/A
- Industry
- FLNC Industrial Machinery/Components
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- EVO Health Care
- Exchange
- FLNC Nasdaq
- EVO Nasdaq
- Market Cap
- FLNC 974.7M
- EVO 1.4B
- IPO Year
- FLNC 2021
- EVO 2021
- Fundamental
- Price
- FLNC $19.46
- EVO $4.09
- Analyst Decision
- FLNC Hold
- EVO Strong Buy
- Analyst Count
- FLNC 19
- EVO 1
- Target Price
- FLNC $9.86
- EVO $7.00
- AVG Volume (30 Days)
- FLNC 9.1M
- EVO 46.5K
- Earning Date
- FLNC 11-24-2025
- EVO 11-05-2025
- Dividend Yield
- FLNC N/A
- EVO N/A
- EPS Growth
- FLNC N/A
- EVO N/A
- EPS
- FLNC N/A
- EVO N/A
- Revenue
- FLNC $2,449,087,000.00
- EVO $912,894,891.00
- Revenue This Year
- FLNC N/A
- EVO N/A
- Revenue Next Year
- FLNC $20.52
- EVO $10.78
- P/E Ratio
- FLNC N/A
- EVO N/A
- Revenue Growth
- FLNC 14.26
- EVO N/A
- 52 Week Low
- FLNC $3.46
- EVO $2.84
- 52 Week High
- FLNC $24.00
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- FLNC 62.99
- EVO 61.32
- Support Level
- FLNC $14.31
- EVO $3.88
- Resistance Level
- FLNC $22.12
- EVO $4.04
- Average True Range (ATR)
- FLNC 2.15
- EVO 0.08
- MACD
- FLNC -0.14
- EVO 0.01
- Stochastic Oscillator
- FLNC 67.18
- EVO 93.09
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.